{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:23:47Z","timestamp":1792571027096,"version":"4.5.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The use of diabetes-related technology, both for insulin administration and glucose monitoring, has shown benefits in older adults with type 1 diabetes (T1D). However, the characteristics of older adults with T1D and their use of technology in real-world situations are not well documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Older adults (age \u226565 years) with T1D, using insulin pump or multiple daily injections (MDI) for insulin administration, and continuous glucose monitoring (CGM) or glucometer (blood glucose monitoring [BGM]) for glucose monitoring were evaluated. Participants wore CGM for 2 weeks, completed surveys, and underwent laboratory evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We evaluated 165 older adults with T1D; mean age 70\u2009\u00b1\u200910 years, diabetes duration 40\u2009\u00b1\u200917 years, and A1C 7.4%\u2009\u00b1\u20090.9% (57\u2009\u00b1\u200910\u2009mmol\/mol). For insulin administration, 63 (38%) were using MDI, while 102 (62%) were using pump. Compared to MDI, pump users were less likely to have cognitive dysfunction (49% vs. 65%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.04) and had lower scores on the hypoglycemia fear survey (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.03). For glucose monitoring, 95 (58%) used CGM, while 70 (42%) used BGM. Compared to BGM, CGM users were more likely to report impaired awareness of hypoglycemia (IAH) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.01), and had lower A1C (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02). Participants who used any technology (pump or CGM) had lower A1C (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.04, 0.006), less hypoglycemia \u226454\u2009mg\/dL (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0006, &lt;0.0001) and &lt;70\u2009mg\/dL (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0002, 0.0001), and fewer glycemic excursions (coefficient of variation %) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0001, &lt;0.0001), while reporting more IAH (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.04,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.006) and diabetes distress (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02, 0.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Older adults with T1D who use newer diabetes-related technology had better glycemic control, lower hypoglycemia risk, and fewer glycemic excursions. However, they were more likely to report IAH and diabetes-related distress.<\/jats:p>\n                    <jats:p>\n                      Clinical\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/trials.gov\">trials.gov<\/jats:uri>\n                      NCT03078491.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2021.0246","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:42:18Z","timestamp":1631702538000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":46,"title":["Use of Technology in Older Adults with Type 1 Diabetes: Clinical Characteristics and Glycemic Metrics"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6917-4197","authenticated-orcid":false,"given":"Medha","family":"Munshi","sequence":"first","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."},{"name":"Beth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Slyne","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai'Quann","family":"Davis","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Michals","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Sifre","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dewar","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Atakov-Castillo","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-1160","authenticated-orcid":false,"given":"Elena","family":"Toschi","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Clinical Research, Boston, Massachusetts, USA."},{"name":"Beth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1006098"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2008.0016"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2756"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805017"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19975"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2855"},{"key":"e_1_3_5_8_2","article-title":"Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review","volume":"7","author":"Fazeli Farsani S","year":"2017","unstructured":"Fazeli Farsani S, , Brodovicz K, , Soleymanlou N, et al.: Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open, 2017; 7:e016587.","journal-title":"BMJ Open"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3790-6"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817704445"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816643542"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817702657"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6928"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2011.8.254"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0215"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1801"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00198"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.27.1.9"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1140"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1229"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1600"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610296002505"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.4.517"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1343"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.03.032"},{"key":"e_1_3_5_27_2","unstructured":"Ware JE Kosinski M Keller SD : SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston MA: Health Assessment Lab 1994."},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1928"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1631"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0016"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14314"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2010.09.005"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2021.0246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:10Z","timestamp":1777399990000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2021.0246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1089\/dia.2021.0246"],"URL":"https:\/\/doi.org\/10.1089\/dia.2021.0246","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}